Lenus Therapeutics, LLC

Lenus Therapeutics, LLC develops RGN‑137 dermal gel containing thymosin beta‑4 for the treatment of epidermolysis bullosa. In a single-masked Phase 2 trial, the company reported complete wound healing of the index lesion in the first subject enrolled. The study design allows direct comparison between placebo and active treatment on paired wounds within each patient. The company aims to advance to Phase 3 based on these results[3][8].

RGN‑137 has multiple mechanisms including promotion of wound healing, cell protection, migration, and tissue integrity. No approved therapies exist for EB beyond supportive care.

Other pipeline activities include dry eye syndrome and previously acute myocardial infarction[2][7].

The company operates as a joint venture between GtreeBNT Co., Ltd. and Yuyang DNU Co., Ltd., with rights licensed from RegeneRx Biopharmaceuticals.

Clinical trial NCT03578029 was terminated at Phase 2 for EB; ongoing development status may vary by region or indication[2].

No commercial products are yet approved.